With BioNTech and Moderna advancing personalised cancer vaccine trials, CEPI backing rapid response platforms, and emerging innovations in saRNA, circRNA, and gene editing, the mRNA field is experiencing a new era of opportunity.

As the industry shifts from pandemic to long-term therapeutic promise, drug developers face mounting pressure to reduce production timelines, de-risk regulatory submissions, and scale robust, reproducible, and compliant mRNA platforms.

The 4th mRNA Process Development & CMC Summit returns as the world’s only flagship forum dedicated to overcoming bottlenecks from designer enzymes and IVT to purification and room temperature stabilisation - helping mRNA therapeutic and vaccine developers deliver safer and more effective mRNA drugs to patients.

With focused content spanning DNA material sourcing, dsRNA control, in-process analytics, next-gen formulations, digital twins, lyophilization, saRNA, and regulatory readiness, this is the only event where the entire mRNA manufacturing ecosystem comes together to drive real-world implementation and clinical impact.

Whether you're scaling up, building out analytical and CMC control strategies, or navigating evolving FDA expectations, this summit will arm you with the technical depth, regulatory clarity, and peer insights needed to produce mRNA drugs faster, smarter, and more confidently.

Join the mRNA power table with Sanofi, GSK, Moderna, AstraZeneca, CSL, BioNTech, CEPI, US Pharmacopeia, CureVac, and Editas Medicines, along with 175+ global experts to walk away with the ultimate mRNA manufacturing roadmap.